Recent Updates
Recently added Catalysts
TNDM Negative Sentiment

Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

Key Takeaway: Tandem Diabetes Care, Inc. is facing a lawsuit due to allegations it misled investors regarding its 2022 sales forecasts. Originally projecting sales between $835 million and $845 million, the company revised its forecast downward to $800 to $805 million, citing increased competition and economic challenges. This significant change led to a sharp decline in the company's stock price by over 28%. The Portnoy Law Firm is encouraging affected investors to contact them for assistance in recovering their losses from the allegations during the class period.
Price reaction · baseline $15.31 (2023-11-06 close) · hit after-hours · clean, no other TNDM news in the window
day 0 close
+6.2%
day 1
+1.4%
day 3 · peak
-6.7%

Market Sentiment Analysis

CONCERNS & RISKS

  • Tandem Diabetes Care revised its 2022 sales forecast downward, indicating potential financial instability.
  • The stock price dropped by approximately 28.37% following the disappointing sales projections.
  • The lawsuit suggests that investors were misled by overly optimistic sales projections and hidden adverse facts.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
tozadenant
Phase 1 · N/A, as Healthy Volunteers

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the “Class Period”)
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
As per the allegations in the Complaint, Tandem is a global medical technology company specializing in the development, manufacturing, and marketing of various consumer technologies and software designed for managing diabetes care at home. Their flagship product, the "t:slim X3," is an FDA-approved at-home insulin pump, and the company also offers web-based applications to assist users in monitoring and treating diabetes.
The Plaintiff asserts that the Defendants provided sales projections for Tandem for the year 2022, ranging from "$835 million to $845 million," with anticipated annual growth of "19 percent to 20 percent" compared to 2021. The Plaintiff contends that these statements were materially misleading and concealed important adverse facts.
However, on November 2, 2022, Tandem significantly revised its 2022 sales forecast downward to a range of "$800 to $805 million." This substantial adjustment was attributed to factors such as heightened competition in the diabetes care industry, complications stemming from the COVID pandemic, and broader economic influences like inflation.
Following this announcement, Tandem's common stock experienced a decline of $14.57 per share, which amounted to approximately 28.37%, ultimately closing at $36.77 per share on November 3, 2022.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Frequently Asked Questions

How can I contact the Portnoy Law Firm for help?

You can reach attorney Lesley F. Portnoy at 844-767-8529 or lesley@portnoylaw.com.

What is the lawsuit concerning Tandem Diabetes Care about?

The lawsuit concerns claims from investors who purchased Tandem securities between August 3 and November 2, 2022.

What caused Tandem's stock decline in November 2022?

Tandem revised its 2022 sales forecast downward, impacting stock value due to competition and economic factors.

Is there a cost for investors to learn about their options?

No, investors can contact the firm at no cost for a case evaluation and their options.

What is the primary product of Tandem Diabetes Care?

Tandem's primary product is the FDA-approved t:slim X3 insulin pump for diabetes management.

Last updated: Nov 7, 2023